{"id":"NCT00626431","sponsor":"Abbott","briefTitle":"A Study of Leuprolide to Treat Prostate Cancer","officialTitle":"A Phase 3, Multi-Center, Open-Label, Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Two 6-Month Leuprolide Formulations, in Subjects With Prostatic Adenocarcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-02","primaryCompletion":"2009-08","completion":"2009-09","firstPosted":"2008-02-29","resultsPosted":"2010-11-01","lastUpdate":"2011-07-19"},"enrollment":310,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Leuprolide acetate - Formulation A","otherNames":["Lupron","leuprorelin","gonadotropin hormone-releasing hormone (GnRH)","luteinizing hormone-releasing hormone (LHRH)"]},{"type":"DRUG","name":"Leuprolide acetate - Formulation B","otherNames":["Lupron","leuprorelin","gonadotropin hormone-releasing hormone (GnRH)","luteinizing hormone-releasing hormone (LHRH)"]}],"arms":[{"label":"Leuprolide acetate - Formulation A","type":"EXPERIMENTAL"},{"label":"Leuprolide acetate - Formulation B","type":"EXPERIMENTAL"}],"summary":"To assess the efficacy and safety of 2 new formulations of leuprolide acetate 45 mg 6-month depot, Formulation A or Formulation B, for the treatment of patients with prostate cancer. A formulation will be deemed successful if the percentage of subjects with suppression of testosterone to \\<= 50 ng/dL from Week 4 to Week 48 is not less than 87%, (the lower bound of the 2-sided 90% confidence interval), a protocol-specified criterion.","primaryOutcome":{"measure":"Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation A: Intent-to-treat (ITT) Population for the Primary Endpoint.","timeFrame":"Week 4 to Week 48","effectByArm":[{"arm":"Leuprolide Acetate - Formulation A","deltaMin":93.6,"sd":2.05}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":18},"locations":{"siteCount":63,"countries":["United States"]},"refs":{"pmids":["22025196"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":151},"commonTop":["hot flush","injection site pain","arthralgia","fatigue","constipation"]}}